Hypoxia as a predictor of mortality among patients admitted with COVID-19 disease in three referral hospitals in Kenya, October 2020 to December 2021
Anthony Waruru,Jonesmus Mutua Wambua,James Mbai,Frank Victor Otieno,Mary Mwangome,Peninah Munyua,Wanjiru Waruiru,Sasi Jonnalagadda,Carol Ngunu,Annastacia K Muange,James Otieno,Dickens Onyango,Nelly Muturi,Anne Njoroge
DOI: https://doi.org/10.1101/2024.10.17.24315667
2024-10-18
Abstract:Introduction: Using peripheral oxygen saturation (SpO2) measurement is a cost-effective and reliable approach to assess the need for oxygen supplementation in patients admitted with coronavirus disease 2019 (COVID-19). Patients who have a SpO2 level of <95% are considered hypoxic and, per COVID-19 management guidelines, should receive oxygen supplementation. We sought to determine whether hypoxia at admission predicted adverse COVID-19 outcomes including mortality among patients admitted with COVID-19 disease in Kenya.
Methods: The study was a cross-sectional retrospective medical chart review of patients hospitalized with COVID-19 between October 1, 2020, and December 31, 2021 in three purposively selected health facilities in Kilifi, Nairobi and Kisumu. We explored the differences in proportions of categorical variables using the χ2 test and assessed predictors (selected a priori) of mortality among patients with hypoxia using Cox proportional hazards models. Using the Kaplan-Meier method, we also computed survival probabilities by hypoxia status for patients on room air or oxygen supplementation and produced survival graphs.
Results: Of the 1,124 COVID-19 patients, 94.8% had documented SpO2 measurements at admission, and 81.4% were found to have hypoxia, with 39.9% of hypoxic patients not exhibiting dyspnea. Hypoxic patients compared to those with normal oxygen saturation levels were significantly older (60+ years: 44.6 vs. 24.4%) and had a higher prevalence of dyspnea (60.1 vs. 36.9%), higher pulse rate (38.2 vs. 24.6%), and hypertension (40.4 vs. 25.8%), p<0.001. Oxygen supplementation was provided to only 68.6% of hypoxic patients. Mortality was notably higher in hypoxic patients versus those with normal SpO2 (38.0% vs. 13.6%, p<0.001), with hypoxia being a key predictor of death. Hypoxic, older patients (≥60 years), and those with dyspnea had a higher risk of death (adjusted hazard ratio: 1.9 [95% confidence interval (CI):1.2–2.8], 1.8 [95% CI 1.3-2.6] and 1.5 [95% CI 1.2-2.0], respectively). Regardless of dyspnea or oxygen supplementation, survival probabilities were worse for hypoxic patients (p<0.001).
Conclusions: Hypoxia was prevalent among hospitalized COVID-19 patients, even without respiratory distress symptoms. These findings underscore the importance early identification and management of hypoxia in COVID-19 patients, thereby guiding clinical care and improving outcomes, particularly for older or sicker patients.
Respiratory Medicine